Navigation Links
Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Date:7/23/2008

lification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver that is closely aligned with an international complement biology research network organized by Michael Holers, M.D., one of the company's founders. For more information, visit http://www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to development of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.

Media Contacts:

David Schull or Robert Flamm, Ph.D.

Russo Partners

(212) 845-4271

david.schull@russopartnersllc.com

robert.flamm@russopartnersllc.com


'/>"/>
SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
2. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
3. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
4. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
5. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
6. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
7. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
8. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
9. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Silence Therapeutics Announces Board Changes
11. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ov. 20 Soligenix, Inc. (...y), formerly known as DOR BioPharma, Inc., a late-...it has formed a consortium to develop thermostable... acting vaccines. Soligenix received a $9.4 millio... Infectious Diseases (NIAID), a division of the Na...
(Date:11/19/2009)...Nov. 19 BioCryst Pharmac...e pricing of a public offering of 5,000,000 shares... in gross proceeds of $48.75 million. All of the ...n effective shelf registration statement previousl...n. BioCryst has also granted the underwriters a 3...
(Date:11/19/2009)...ov. 19 In a series of ne..., Heska Corporation (Nasdaq: HSKA ) ("Heska" or t...w and improved website. The upgraded site is the ...rogramming to align the site with the company,s ne...go: http://www.newscom.com/cgi-bin/prnh/20000622...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3OPAXIO 28TM 29 Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annu 5050 1Open innovation networks are one key to improved care 58222 1Open innovation networks are one key to improved care 58222 2Open innovation networks are one key to improved care 58222 3Open innovation networks are one key to improved care 58222 4Open innovation networks are one key to improved care 58222 5Fish fend off invading germs with an initial response similar to the one found in people 10082 1Fish fend off invading germs with an initial response similar to the one found in people 10082 2
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ...oday announced that it will present updated result...one-year survival data, during a,poster discussion...Study of,Lung Cancer,s (IASLC) 12th World Conferen... Poster number: PD6-1-1 Title: A phase 2 study o...
... (Nasdaq:,VICL) announced today that results from ...using a plasmid DNA (pDNA) vaccine developed by th...Vical, reinforced previously,reported Phase 1 conc...,vaccine regimen was safe and well-tolerated, and ...in up to 70% of the vaccine recipients. "These re...
Other Medicine Technology:Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 2Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 3Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3
(Date:11/21/2009)... , "This bill provides for an unprecedente...health care about if it is not for preserving and ... it must be defeated." Charmaine Yoest ,, WA...cans United for Life Action President and CEO Dr. ... Senate by releasing the following statement: ,...
(Date:11/21/2009)... , WASHINGTON, Nov. 21 /PRNewswire-USNewswire...o eliminate onchocerciasis (river blindness) in th...e of the disease in recent years, as evidenced by ...ing mass drug administration in six endemic countr...al meeting of the American Society of Tropical Med...
(Date:11/21/2009)..., LONDON, November 21, 2009 /PRNewswire-Fir... Test Test Test Test Test Test Test Test Test Test... Test Test Test Test Test Test,Test Test Test Test... More test More test More test More test More tes...t More test More test More test More test More,tes...
(Date:11/21/2009)... Innovative medical apparel co...erence , San Clemente, Ca...aker of breakthrough medical apparel, today announ...n display at Medica 2009, a leading international ...dorf, Germany. Medelita inaugurates its men,s coll...
(Date:11/21/2009)... Eric J. Hall, president and c...on of America (AFA) issued the following statement...etection as part of the new annual wellness for Me...on and Affordable Care Act" that was introduc..., NY (PRWEB) November 21, 2009 -- Eric J. Hall, pr...
Breaking Medicine News(10 mins):Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3
...t Listed on Product Labels Due to Weak Regulatory ...ting claims like "gentle" and "pure," dozens of to...d with the cancer-causing chemicals formaldehyde a...abels because contaminants are exempt from labelin...
...March 12 For the past three decades, employers ha...e costs. Now some are pinning their hopes on a rel..., which link high-deductible health insurance plan...ent in Health Care -- 30 Years into the Experiment...
...perts in cancer and nutrition are meeting in Zuric...edge research in one of the most important and fie...k between diet and cancer. , There is growing ev...so have a negative impact on cancer management and...
...- The long tails sported by many male birds in the...and a distinct disadvantage when fleeing predators...keley, biologists shows that they exact only a min...cent, which means the bird has to visit 1 to 3 per...
...ass., March 12 North American application activit... up +1.1% in February, year-over-year, according t...from January to February 2009 was up +12.9%. Year...butable to the Life Index methodology rather than ...
...Partners Offer Consumers Chance to Win Tickets to ...RSIPPANY, N.J., March 12 alli announced today a s...ity to attend a private Wynonna Judd concert in Na...nd,s spokesperson, in an intimate setting while sh...
Other Medicine News:Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 2Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 3Health News:EBRI Policy Forum: Consumer/Patient Engagement in Health Care - 30 Years On 2Health News:New data on link between cancer and nutrition discussed at European symposium 2Health News:Long, sexy tails not a drag on male birds 2Health News:Long, sexy tails not a drag on male birds 3Health News:Long, sexy tails not a drag on male birds 4Health News:MIB Life Index Reports North American Life Insurance Activity up 1.1% in February 2Health News:MIB Life Index Reports North American Life Insurance Activity up 1.1% in February 3Health News:Wynonna Judd and alli Host Private Concert in Nashville 2
Ocular Three Mirror 10 mm Gonio
Ocular Magna View Gonio
Ocular Koeppe Diagnostic
Mcintyre Cannula
Medicine Products: